RecruitingNot ApplicableNCT03967834

Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group


Sponsor

Institut Claudius Regaud

Enrollment

400 participants

Start Date

Apr 26, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

This trial is a translational, open-label, multi-sites, prospective and retrospective cohort study of 500 patients aimed at clinical and biological characterization of sarcoma of rare subtype. 400 patients will be included in this prospective cohort study; they will be identified in the investigating centers in the context of either routine care or a clinical study protocol. Retrospective cases of patients (100 cases in total) will be identified in all centers through the GSF/GETO clinical databases already setted up (including the clinical base Conticabase).


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study looks at how the immune system interacts with rare types of soft tissue cancer (called sarcoma) in adults. Researchers want to collect tumor samples and blood to understand why these cancers behave the way they do, which could lead to better treatments. **You may be eligible if...** - You are 18 or older - You have been diagnosed with one of nine specific rare sarcoma types (such as Clear Cell Sarcoma, Epithelioid Sarcoma, or Alveolar Soft Part Sarcoma) - Your disease is localized, locally advanced, or has spread to other parts of the body - You have stored tumor tissue from your original diagnosis - You are being seen at a participating center **You may NOT be eligible if...** - You are under 18 - You have already started treatment for localized disease (other than surgery) - Your performance level (ability to carry out daily activities) is very poor (ECOG 4) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPatient with Soft Tissue Sarcoma

* Tumor specimens will be collected for the study at diagnosis. * A blood sample will be collected in all included patients at baseline, after the completion of the treatment (for patients included with a localized disease) or at the time of the first tumoral evaluation (for patients included with a metastatic disease), and at the time of progression. * Patient's data (clinical, biological and disease data) will also be collected at baseline visit and then at each time point planned in the center for clinical benefit assessment (i.e. every 2 or 3 months) until progression or for a maximum duration of 5 years.


Locations(20)

Chu Besancon - Site Jean Minjoz

Besançon, France

Institut Bergonié

Bordeaux, France

Centre Jean Perrin

Clermont-Ferrand, France

Centre Georges François Leclerc

Dijon, France

Centre Oscar Lambret

Lille, France

Chu Dupuytren

Limoges, France

Centre Leon Berard

Lyon, France

Institut Paoli-Calmettes

Marseille, France

Chu de Marseille - Hopital de La Timone

Marseille, France

Centre Antoine Lacassagne

Nice, France

Hôpital Cochin - Site Port-Royal

Paris, France

Institut Curie

Paris, France

Chu Poitiers

Poitiers, France

Institut Godinot

Reims, France

Centre Eugene Marquis

Rennes, France

Institut de Cancerologie de L'Ouest - Site Rene Gauducheau

Saint-Herblain, France

Hôpitaux Universitaires de Strasbourg

Strasbourg, France

Institut Universitaire du Cancer Toulouse - Oncopole

Toulouse, France

Institut de Cancerologie de Lorraine

Vandœuvre-lès-Nancy, France

Institut Gustave Roussy

Villejuif, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03967834


Related Trials